Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
4RCHOP+4R vs 6RCHOP+2R in Naive, Low-risk, Non-mass DLBCL
NCT05018520Phase 3Recruiting
- Sponsor
- Ruijin Hospital
- Start
- Sep 2021
- Primary completion
- Jun 2028
- Modality
- Monoclonal Antibodies, DNA Intercalators/Alkylators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 3 trial of rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone in diffuse large B-cell lymphoma (DLBCL), sponsored by Ruijin Hospital. Started Sep 2021; status: recruiting.
02
Drugs
rituximabcyclophosphamidedoxorubicinvincristineprednisone
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT05018520.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05018520.